Shay Capital’s Entrada Therapeutics TRDA Stock Holding History

Shay Capital’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,548	Closed	-$272K	–	639
2026 Q1	$272K	Buy	+21,548	New	+$247K	0.02%	349

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Shay Capital's TRDA Position: Q2 2026 in Review

Shay Capital sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 21,548 shares — an estimated $272K sold.

Shay Capital first reported a position in TRDA in Q1 2026 and held it in 1 quarter. The position peaked at $272K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Shay Capital reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
Shay Capital sold 21,548 Entrada Therapeutics shares in Q2 2026, an estimated $272K.
Shay Capital first reported a position in Entrada Therapeutics in Q1 2026 and held it in 1 quarter.
Shay Capital's Entrada Therapeutics position peaked at $272K in Q1 2026.
128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.